QuantHealth, an AI clinical trial simulation company, said it raised $45 million in a Series B funding round led by Qumra Capital.
The round included participation from Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund, Bertelsmann Healthcare Investments, GC Ventures, NewHealth Ventures, Shoni Top Ventures and Esplanade Ventures.
Gallery
Arnon Horev, co-founder and Chief Strategy & Operations and Orr Inbar, CEO and co-founder of QuantHealth
(Photo: Courtesy)
QuantHealth said the funding will be used to expand research and development, grow its workforce and broaden its product portfolio across the clinical and commercial development process. The investment follows eightfold sales growth in 2025, according to the company.
The company’s platform uses AI-driven simulations to help pharmaceutical and biotechnology companies test, optimize and reduce risk in clinical trial design before patients are enrolled or capital is committed. QuantHealth said it aims to move drug developers away from relying mainly on historical benchmarks and assumptions when planning trials.
“Today, clinical development decisions are still largely made through real-world iteration — running trials, waiting for results and adjusting at significant cost and risk. We’re fundamentally changing that model,” said Orr Inbar, CEO and co-founder of QuantHealth. “With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital. This funding allows us to scale that approach, making simulation a standard step in development and fundamentally improving how drugs are brought to market.”
Clinical trials remain among the most expensive and uncertain parts of drug development. QuantHealth said more than 90% of drugs that enter clinical development ultimately fail, with about 75% failing because of efficacy or safety issues. The company said that pressure has pushed pharmaceutical and biotech companies to adopt predictive technologies to guide trial planning and decision-making.
Reut Yehuda Golan, partner at Qumra Capital
(Photo: Courtesy)
To date, QuantHealth has simulated more than 600 clinical trials across 30 indications, reaching up to 90% predictive accuracy. The company plans to expand to more than 40 indications across core therapeutic areas including oncology, cardiometabolic disease and inflammation.
“AI has already transformed drug discovery, and clinical trials are the next frontier,” said Reut Yehuda Golan, partner at Qumra Capital. “It’s a market in which hundreds of billions of dollars are spent annually on clinical trials, and one that is ripe for a smarter, more efficient approach.”
QuantHealth said it works with 12 of the world’s top 20 pharmaceutical companies. Its platform is designed to support trial design, execution, commercial planning and competitive assessment across early- and late-stage trials.
The company did not disclose its valuation.
